

Supplemental Tables for:  
Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the POLA cohort  
Vincent Esteyrie et al.

**Table S1.** Patient's clinical and demographic characteristics in the cohort of the three centers of Paris, Lyon and Toulouse

	RT + temozolomide N = 72	RT + PCV N = 67	Total N = 139	p
Median age (range)	39 (20 ; 71)	37 (19 ; 67)	38 (19 ; 71)	<b>0.0139</b>
Sex				
Male	44 (61.1%)	35 (52.2%)	79 (56.8%)	0.2913
Female	28 (38.9%)	32 (47.8%)	60 (43.2%)	
Performance Status				
0	45 (63.4%)	44 (68.8%)	89 (65.9%)	0.3763
1	18 (25.4%)	17 (26.6%)	35 (25.9%)	
2	8 (11.3%)	3 (4.7%)	11 (8.1%)	
Missing	1	3	4	
Initial surgery				
Biopsy	13 (18.1%)	10 (14.9%)	23 (16.5%)	0.6197
Resection	59 (81.9%)	57 (85.1%)	116 (83.5%)	
Localisation				
Frontal	56 (77.8%)	46 (68.7%)	102 (73.4%)	0.2241
Temporal	22 (30.6%)	33 (49.3%)	55 (39.4%)	0.0243
Parietal	11 (15.3%)	8 (11.9%)	19 (13.7%)	0.5671
Occipital	7 (9.7%)	3 (4.5%)	10 (7.2%)	0.3288
Side				
Right	36 (50.0%)	29 (43.3%)	65 (46.8%)	0.7154
Left	33 (45.8%)	34 (50.7%)	67 (48.2%)	
Median	3 (4.2%)	4 (6.0%)	7 (5.0%)	
IDH mutation type				
IDH 1	72 (100%)	66 (98.5%)	138 (99.3%)	
IDH 2	0 (0.0%)	1 (1.5%)	1 (0.7%)	
Sub-ventricular zone contact				
Yes	52 (83.9%)	46 (75.4%)	98 (79.7%)	0.2437
No	10 (16.1%)	15 (24.6%)	25 (20.3%)	
Missing	10	6	16	
MIB1				
Median (range)	10 (1 – 80)	10 (2 – 30)	10 (1 – 80)	0.8879
≤10%	31 (58.5%)	39 (65.0%)	70 (61.9%)	0.4769
>10%	22 (41.5%)	21 (35.0%)	43 (38.1%)	
Missing	19	7	26	

Supplemental Tables for:  
Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the POLA cohort  
Vincent Esteyrie et al.

Table S2. Univariable analysis of progression-free survival in the national POLA cohort

	Events	4 years Survival	HR	CI 95%	p
Treatment					<b>p= 0.0074</b>
RT + PCV	32 / 122	70.82%	0.58	[ 0.38 ; 0.87]	
RT + temozolomide	89 / 189	53.48%	1.00		
Initial surgery					<b>p&lt; 0.0001</b>
Resection	89 / 254	64.00%	0.45	[ 0.30 ; 0.68]	
Biopsy	32 / 55	37.52%	1.00		
Performance Status					<b>p= 0.0015</b>
0 - 1	79 / 232	65.87%	0.37	[ 0.20 ; 0.70]	
≥ 2	11 / 18	34.74%	1.00		
Sub-ventricular zone contact					p= 0.8130
Yes	38 / 98	59.80%	1.00		
No	13 / 36	55.30%	0.93	[ 0.49 ; 1.74]	
Localisation					
Frontal	82 / 213	61.92%	0.83	[ 0.55; 1.26]	p= 0.3814
Parietal	21 / 49	58.05%	1.12	[ 0.70; 1.81]	p= 0.6283
Temporal	46 / 111	52.90%	1.27	[ 0.87; 1.86]	p= 0.2110
Occipital	8 / 18	50.24%	1.17	[ 0.57; 2.40]	p= 0.6728
Mib1					<b>p= 0.0201</b>
≤10%	46 / 146	69.72%	0.64	[ 0.43; 0.93]	
>10%	60 / 136	52.56%	1.00		
Age			1.01	[1.00; 1.03]	p= 0.0828

Supplemental Tables for:  
Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the POLA cohort  
Vincent Esteyrie et al.

**Table S3.** Univariable analysis of overall survival in the national POLA cohort

	Events	4 years Survival	HR	CI 95%	p
Treatment					p = 0.0675
RT + PCV	14 / 122	84.31%	0.57	[ 0.30 ; 1.05]	
RT + temozolomide	51 / 189	76.63%	1.00		
Initial surgery					<b>p = 0.0420</b>
Resection	48 / 254	80.29%	0.57	[ 0.32 ; 0.99]	
Biopsy	17 / 55	73.94%	1.00		
Performance Status					<b>p = 0.0004</b>
0 -1	38 / 232	83.73%	0.26	[ 0.11 ; 0.58]	
≥ 2	7 / 18	53.48%	1.00		
Sub-ventricular zone contact					p = 0.4833
Yes	17 / 98	81.86%	1.00	[ 0.58 ; 3.18]	
No	8 / 36	82.25%	1.36		
Localisation					
Frontal	48 / 213	77.40%	1.25	[ 0.68; 2.32]	p = 0.4733
Parietal	11 / 49	80.24%	0.85	[ 0.43; 1.69]	p = 0.6429
Temporal	21 / 111	81.63%	0.89	[ 0.52; 1.51]	p = 0.6629
Occipital	5 / 18	79.06%	1.26	[ 0.50; 3.16]	p = 0.6191
Mib1					<b>p = 0.0005</b>
≤10%	19 / 146	89.69%	0.39	[ 0.22; 0.67]	
>10%	39 / 136	68.62%	1.00		
Age			1.02	[1.00; 1.04]	p= 0.0534